TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00542685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: Capsules, oral, 300 mg BID, 8 weeks with 2 week taper.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, oral, placebo BID, 8 weeks with 2 week taper.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: Capsules, oral, 225 mg BID, 8 weeks with 2 week taper.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: Capsules, oral, 175 mg BID, 8 weeks with 2 week taper.
Study: NCT02494700

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo orbital EBRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orbital Radiation
Description: Participants receive radiation to entire involved orbit for a total dose of 4 Gy in 2 fractions over two consecutive days with external beam radiotherapy. If there is stable disease or progressive disease, an additional 20 Gy administered to involved site. If there are two consecutive evaluations with no change in disease burden then an additional 20 Gy administered. At one year if there is persistent disease, an additional 20 Gy administered to involved site.
Study: NCT03935620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Milieu teaching
Description: Enhanced Milieu Teaching (EMT) an evidence-based, naturalistic language intervention that has been optimized to address the specific language and communication deficits associated with DS. EMT is a parent-implemented intervention that involves home-visits during which clinicians teach parents to support their child learning language during typical parent-child interactions at home (play with toys, music, book reading, and snack time). Clinicians follow an evidence-based instructional framework called Teach-Model-Coach-Review to teach parents language support strategies.
Study: NCT04374968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flood restriction cuff
Description: Blood flow restriction cuffs will be used as an augment to physical therapy
Study: NCT04318717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is commercially available

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy
Description: It is preferred to leave at least 48 hours between fractions. Daily imaging to verify accurate set-up is mandatory.
Study: NCT02669238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexplanon®
Description: Subcutaneous implant (Nexplanon®) containing etonogestrel 68 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minidril®/Leeloo®
Description: continuous per os administration of oestroprogestative treatment. 1 pill a day First line: Minidril® (Levonogestrel 0.15 mg / Ethinylestradiol 0.03 mg) Second line: Leeloo® (Levonogestrel 0.1 mg / Ethinylestradiol 0.02 mg)
Study: NCT03557827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic Therapy with indocyanine green and diode laser
Description: mechanical debridement by periodontal curets plus Indocyanine green solution activated by diode laser. The diode laser is classified as a Class I medical device according to the Directive 93/42/EEC

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Mechanical debridement alone
Description: Mechanical debridement by periodontal curets alone
Study: NCT01861171

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Green Tea
Description: Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Green Tea
Description: Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
Study: NCT00842764

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Holmium: YAG laser
Description: Minimally Invasive Holmium:YAG laser Blepharoplasty
Study: NCT04383899

Intervention type: OTHER
Intervention: Questionnaire
Description: All patients testing positively for COVID-19, with completed questionnaires. As appropriate, the duration of the study will be at least the time to complete the questionnaire for non-hospitalized patients, and for those who are hospitalized, they will be followed until hospital discharge or death to ascertain outcome.

Intervention type: OTHER
Intervention: Questionnaire
Description: All patients testing positively for COVID-19, with completed questionnaires. As appropriate, the duration of the study will be at least the time to complete the questionnaire for non-hospitalized patients, and for those who are hospitalized, they will be followed until hospital discharge or death to ascertain outcome.
Study: NCT02983396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic accuracy of Mini Relf Device
Description: Evaluation of the Mini Relf Device when it is applied on daily basis at home and during coronary angioplasty at 60 second acute coronary occlusion angioplasty
Study: NCT02193698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide+Dexamethasone
Description: Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)
Study: NCT04543409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC), 1 mL fill volume
Study: NCT00928798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Application of rapamycin 1 mg/ml oral solution to one predefined skin area on one facial half, twice daily 0,25 ml, during 6 months. The other facial half will be similarly treated with a placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Application of placebo to one predefined skin area on one facial half, during 6 months. The other facial half will be similarly treated with rapamycin 1 mg/ml oral solution
Study: NCT03530566

Intervention type: OTHER
Intervention: PnK® Method
Description: A multidisciplinary program of weight loss based on diet (initially very low ketogenic diet), physical activity and emotional support

Intervention type: OTHER
Intervention: standard diet
Description: standard low calorie diet for weight loss
Study: NCT01052844

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, given orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 300mg, orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
Study: NCT02147002

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gold omega 3
Description: At the beginning and at the end of the observation period, besides the clinical test, some other tests will be carried out: echocardiography, pulse wave velocity (PWV), ambulatory blood pressure monitoring (ABPM). Blood will be collected for laboratory tests such as: lipid profile, uric acid, CRP, BUN, creatinine, morphology, Ca, P, Ca x P, ionogram, xanthine oxidase, MPC1,Omega-3 acids, resolvin and protectins - the metabolites of Omega-3 acids, creatinine excretion, MPC1 excretion and excretion of uric acid.The patients will be treated with Omega-3 acids as a Gold Omega 3 preparation (2x1 capsule where 1 capsule = 1000 mg) for 6 months.
Study: NCT03750591

Intervention type: DRUG
Intervention: Herbal medicine
Description: Herbal medicine will be mainly administered in water-based decoction (120ml) and dried powder (2g) form (the ingredients are mainly, but not restricted to: Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).

Intervention type: PROCEDURE
Intervention: Chuna manual therapy
Description: Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving highvelocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.~Chuna manipulation will be administered at the physician's discretion.

Intervention type: PROCEDURE
Intervention: Bee venom pharmacopuncture
Description: Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test.~Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26gauze(G) x 1.5 syringe, Shinchang medical co., Korea).

Intervention type: PROCEDURE
Intervention: Pharmacopuncture
Description: Pharmacopuncture consisting of select herbal ingredients will be administered at Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26gauze(G) x 1.5 syringe, Shinchang medical co., Korea).

Intervention type: PROCEDURE
Intervention: Acupuncture
Description: Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.

Intervention type: PROCEDURE
Intervention: Electroacupuncture
Description: Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.

Intervention type: PROCEDURE
Intervention: Cupping
Description: Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.

Intervention type: OTHER
Intervention: Other intervention(s)
Description: Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
Study: NCT00355524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC114
Description: TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC114
Description: TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC114
Description: TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC114
Description: TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC114
Description: TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC114
Description: TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC114
Description: TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.
Study: NCT04096157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate IV
Description: Intravenous (IV) via nasogastric (NG) tube
Study: NCT00355524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.
Study: NCT00660491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: moderate intensity exercise group, and high intensity exercise group
Study: NCT01091363

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: 10 minute brief cessation counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deep Cultural
Description: Deep culturally tailored cognitive behavioral therapy
Study: NCT03271996

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary closure
Description: Asymmetric skin incision and total excision of the lesion with monopolar scalpel. Accurate hemostasis, creation of a cutaneous-subcutaneous flap, primary closure with non-absorbable sutures, optional aspiration drainage.
Study: NCT02147002

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gold omega 3
Description: At the beginning and at the end of the observation period, besides the clinical test, some other tests will be carried out: echocardiography, pulse wave velocity (PWV), ambulatory blood pressure monitoring (ABPM). Blood will be collected for laboratory tests such as: lipid profile, uric acid, CRP, BUN, creatinine, morphology, Ca, P, Ca x P, ionogram, xanthine oxidase, MPC1,Omega-3 acids, resolvin and protectins - the metabolites of Omega-3 acids, creatinine excretion, MPC1 excretion and excretion of uric acid.The patients will be treated with Omega-3 acids as a Gold Omega 3 preparation (2x1 capsule where 1 capsule = 1000 mg) for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gold omega 3
Description: At the beginning and at the end of the observation period, besides the clinical test, some other tests will be carried out: echocardiography, pulse wave velocity (PWV), ambulatory blood pressure monitoring (ABPM). Blood will be collected for laboratory tests such as: lipid profile, uric acid, CRP, BUN, creatinine, morphology, Ca, P, Ca x P, ionogram, xanthine oxidase, MPC1,Omega-3 acids, resolvin and protectins - the metabolites of Omega-3 acids, creatinine excretion, MPC1 excretion and excretion of uric acid.The patients will be treated with Omega-3 acids as a Gold Omega 3 preparation (2x1 capsule where 1 capsule = 1000 mg) for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gold omega 3
Description: At the beginning and at the end of the observation period, besides the clinical test, some other tests will be carried out: echocardiography, pulse wave velocity (PWV), ambulatory blood pressure monitoring (ABPM). Blood will be collected for laboratory tests such as: lipid profile, uric acid, CRP, BUN, creatinine, morphology, Ca, P, Ca x P, ionogram, xanthine oxidase, MPC1,Omega-3 acids, resolvin and protectins - the metabolites of Omega-3 acids, creatinine excretion, MPC1 excretion and excretion of uric acid.The patients will be treated with Omega-3 acids as a Gold Omega 3 preparation (2x1 capsule where 1 capsule = 1000 mg) for 6 months.
Study: NCT02147912

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Aerobic exercise intervention consists of lower (treadmill and cyclette) and upper arts (arm ergometer Davenbike®) training, as well as calisthenic exercises with increasing intensity from a minimum of 80% to a maximum workload for lower arts in a minimum time.
Study: NCT03472066

Intervention type: OTHER
Intervention: Previous conization
Description: a group of women who have been conized,
Study: NCT04096157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate IV
Description: Intravenous (IV) via nasogastric (NG) tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate capsules
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate capsules
Description: Oral
Study: NCT00343798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT03472066

Intervention type: OTHER
Intervention: no previous conization
Description: group with asymptomatic patients on routine second trimester echography
Study: NCT01717144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapeutic education program
Description: The educational program consisted of both individual and collective educational consultations with a therapeutic education nurse
Study: NCT04643821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine, NAC, and calcitriol
Description: iv administration of antioxidant and active vitamin D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine, NAC, and calcitriol
Description: iv administration of antioxidant and active vitamin D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine, NAC, and calcitriol
Description: iv administration of antioxidant and active vitamin D
Study: NCT01993251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melatonin
Description: one capsule, melatonin 0.5 mg, oral, once a day, 30 minutes before bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: one capsule, melatonin 2 mg, oral, once a day, 30 minutes before bedtime
Study: NCT00343798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given IV or PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ex-vivo umbilical cord blood expansion
Description: Undergo double-unit umbilical cord blood transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: double-unit umbilical cord blood transplantation
Description: Undergo double-unit umbilical cord blood transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Optional correlative studies
Study: NCT01993251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: one capsule, melatonin 6 mg, oral, once a day, 30 minutes before bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one capsule, placebo, oral, once a day, 30 minutes before bedtime
Study: NCT01704898

Intervention type: DRUG
Group type: OTHER
Intervention: Efavirenz 600 Test-Stocrin 600 Reference

Intervention type: DRUG
Group type: OTHER
Intervention: Stocrin 600 Reference-Efavirenz 600 Test
Study: NCT02686528

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip Precautions
Description: Hip precautions are functional limitations of the hip replacement prescribed to patients for the first six weeks after surgery and are no hip flexion past 90º, no crossing the legs, and no twisting at the waist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Hip Precautions
Description: Patients will not be prescribed hip precautions in the first 6 weeks after surgery. The hip precautions that will no longer be prescribed are: no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
Study: NCT01683227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening/motivational drug intervention
Description: Screening and brief motivational intervention delivered in the ER to reduce drug use

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Motivational placebo intervention
Description: Screening and brief motivational intervention delivered in the ER to reduce driving and traffic risk
Study: NCT02131532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A brief psychological intervention
Description: This intervention is based on the principle of cognitive-behavioral therapy
Study: NCT04061382

Intervention type: PROCEDURE
Intervention: Venepuncture
Description: One study visit will be conducted by research study staff and blood sampling will be carried out.~Up to three follow-up visits will be conducted for a percentage of participants, where additional blood samples will be collected. The blood sample will initially focus on looking at population immunity to diphtheria, group C invasive meningococcal disease and SARS-CoV-2.

Intervention type: PROCEDURE
Intervention: Venepuncture
Description: One study visit will be conducted by research study staff and blood sampling will be carried out.~Up to three follow-up visits will be conducted for a percentage of participants, where additional blood samples will be collected. The blood sample will initially focus on looking at population immunity to diphtheria, group C invasive meningococcal disease and SARS-CoV-2.
Study: NCT00343798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Description: Correlative studies